TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 47949

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 120
Study: 30445841

Group type: EXPERIMENTAL
Intervention: Combination therapy (losartan plus lisinopril)
Number of subjects: 895

Group type: COMPARATOR
Intervention: Monotherapy (losartan)
Number of subjects: 895
Study: 26464072

Group type: EXPERIMENTAL
Intervention: Multimedia presentation (MP) group
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (traditional verbal consent)
Number of subjects: 93
Study: 26071565

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22620494

Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation (TSI), 300 mg twice daily for 28 days
Number of subjects: 20
Study: 21694613

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 50 mg/d
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/d
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/d
Number of subjects: 951

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 951
Study: 18266876

Group type: EXPERIMENTAL
Intervention: Implant-supported mandibular overdentures (n=49)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional dentures (n=48)
Number of subjects: 97
Study: 16242910

Group type: EXPERIMENTAL
Intervention: Placebo administration with expectation of analgesia
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Placebo administration
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Model including affective qualities of pain and internal affective state
Number of subjects: 19
Study: 12705488

Group type: EXPERIMENTAL
Intervention: Acupressure applied at P6 point half an hour before surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo group with acupressure band tied on P6 point but bead placed away from P6 point
Number of subjects: 50
Study: 10766682

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10, 200 mg/d
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 8612390

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg four times a day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tacrine (40 mg) alone
Number of subjects: 12
Study: 1597980

Group type: EXPERIMENTAL
Intervention: Normothermic systemic perfusion (35 degrees to 37 degrees C; n = 73)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 gm intravenously; n = 63)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Epsilon‐aminocaproic acid (15 gm intravenously; n = 63)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Warm control patients (no drug)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Cold control patients (no drug; n = 20)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Normothermic systemic perfusion, tranexamic acid, and epsilon‐aminocaproic acid
Number of subjects: 146
Study: 6338768

Group type: EXPERIMENTAL
Intervention: Ocular decongestant product 1 (naphazoline hydrochloride + antazoline phosphate)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Ocular decongestant product 2 (naphazoline hydrochloride + pheniramine maleate)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Ocular decongestant product 3 (naphazoline hydrochloride + antazoline phosphate or pheniramine maleate)
Number of subjects: 89
Study: 30136858

Group type: EXPERIMENTAL
Intervention: 24-Style Simplified t'ai chi exercise for 3 months
Number of subjects: 208

Group type: COMPARATOR
Intervention: General daily lifestyle intervention
Number of subjects: 208
Study: 28121044

Group type: EXPERIMENTAL
Intervention: 24 h prophylaxis
Number of subjects: 464

Group type: COMPARATOR
Intervention: 72 h prophylaxis
Number of subjects: 464
Study: 26598919

Group type: EXPERIMENTAL
Intervention: Kan Jang (KJ) oral solution (30 ml/day; 762 mg genuine extracts with standardized contents of 0.2 mg/ml vasicine, 0.8 mg/ml chicoric acid, and 0.03 mg/ml eleutherosides B and E)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Bromhexine hydrochloride (24 mg/30 ml/day)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 177
Study: 24158631

Group type: EXPERIMENTAL
Intervention: CSF drainage
Number of subjects: 26
Study: 22468716

Group type: EXPERIMENTAL
Intervention: Collaborative implementation intentions
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Partner-only
Number of subjects: 257

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 257
Study: 19747359

Group type: EXPERIMENTAL
Intervention: Dermoscopy and short-term sequential digital dermoscopy imaging (SDDI)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Dermoscopy and SDDI
Number of subjects: 63
Study: 17080004

Group type: EXPERIMENTAL
Intervention: 8 days of antibiotics
Number of subjects: 401

Group type: COMPARATOR
Intervention: 15 days of antibiotics
Number of subjects: 401

Group type: COMPARATOR
Intervention: 8 vs. 15 days of antibiotics
Number of subjects: 401
Study: 16338560

Group type: EXPERIMENTAL
Intervention: Capsular bending ring (CBR)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Capsular measuring ring (CMR) alone
Number of subjects: 92
Study: 12456201

Group type: EXPERIMENTAL
Intervention: Wholly stochastic cost-effectiveness analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline clinical trial design
Number of subjects: 0
Study: 9607017

Group type: EXPERIMENTAL
Intervention: Hib (SB) + DTPw in the same syringe
Number of subjects: 230

Group type: COMPARATOR
Intervention: Hib (SB) + DTPw separately
Number of subjects: 230

Group type: COMPARATOR
Intervention: Hib (PM) + DTPw separately
Number of subjects: 230
Study: 8582502

Group type: EXPERIMENTAL
Intervention: Milk-treated sperm
Number of subjects: 41

Group type: COMPARATOR
Intervention: TEST-yolk treated sperm
Number of subjects: 41
Study: 2094341

Group type: COMPARATOR
Intervention: 150 micrograms selenium
Number of subjects: 33

Group type: COMPARATOR
Intervention: 100 micrograms selenium daily for 14 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 639229

Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mg/kg intravenously followed by 320 mg orally over 27 hours)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control (no specific treatment)
Number of subjects: 95
Study: 30807423

Group type: EXPERIMENTAL
Intervention: Pessary use
Number of subjects: 114
Study: 27639190

Group type: EXPERIMENTAL
Intervention: P/EVL
Number of subjects: 185

Group type: COMPARATOR
Intervention: P/CsA
Number of subjects: 185
Study: 25786106

Group type: EXPERIMENTAL
Intervention: Aspartame (100mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control snack bars
Number of subjects: 96
Study: 22773237

Group type: EXPERIMENTAL
Intervention: Nathanson liver retractor
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: liver suspension tape
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: V‐shaped liver suspension technique (V‐LIST)
Number of subjects: 60
Study: 22586903

Group type: EXPERIMENTAL
Intervention: cycloferon (10 days, intramuscularly or orally depending on age)
Number of subjects: 80

Group type: COMPARATOR
Intervention: standard therapy alone
Number of subjects: 80
Study: 19581567

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (dosing range, 1200-2400 mg/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17337726

Group type: EXPERIMENTAL
Intervention: Bioabsorbable arrows
Number of subjects: 100

Group type: COMPARATOR
Intervention: Inside-out suturing
Number of subjects: 100
Study: 16339336

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation for 1 year
Number of subjects: 617

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 617
Study: 11994337

Group type: EXPERIMENTAL
Intervention: 0.27 mg/kg.wk of recombinant human GH with low dose ethinyl E2
Number of subjects: 232

Group type: COMPARATOR
Intervention: 0.27 mg/kg.wk of recombinant human GH with oral placebo
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: 0.36 mg/kg.wk of recombinant human GH with low dose ethinyl E2
Number of subjects: 232

Group type: COMPARATOR
Intervention: 0.36 mg/kg.wk of recombinant human GH with oral placebo
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Early administration of estrogen (low doses)
Number of subjects: 232
Study: 9806584

Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian transposition
Number of subjects: 24
Study: 7702820

Group type: EXPERIMENTAL
Intervention: Polymyxin B‐neomycin‐hydrocortisone drops (single dose intraoperatively)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Polymyxin B‐neomycin‐hydrocortisone drops (5-day course after intraoperative dose)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No antibiotic drops (control group)
Number of subjects: 300
Study: 2792168

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 356524

Group type: EXPERIMENTAL
Intervention: BCNU
Number of subjects: 102

Group type: COMPARATOR
Intervention: CCNU
Number of subjects: 102
Study: 30217770

Group type: EXPERIMENTAL
Intervention: Micronutrient treatment
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 29266450

Group type: EXPERIMENTAL
Intervention: Modified 8-week reminiscence therapy (Group 1: 25 couples, Group 2: 22 couples)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Waiting list (control group, Group 3: 28 couples)
Number of subjects: 75
Study: 27170530

Group type: EXPERIMENTAL
Intervention: Condensed regimen (100 mg twice daily for 2 weeks followed by 200 mg twice daily)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Conservative regimen (50 mg twice daily for 2 weeks, 100 mg twice daily for 3 weeks, followed by 200 mg twice daily)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Condensed regimen
Number of subjects: 498

Group type: COMPARATOR
Intervention: Conservative regimen
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: High-dose ACEI/ARB with condensed regimen
Number of subjects: 498

Group type: COMPARATOR
Intervention: High-dose ACEI/ARB with conservative regimen
Number of subjects: 498

Group type: COMPARATOR
Intervention: Low-dose ACEI/ARB with conservative regimen
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Low-dose ACEI/ARB with condensed regimen
Number of subjects: 498
Study: 25404439

Group type: EXPERIMENTAL
Intervention: Manual Vacuum Aspiration (MVA) as outpatient procedure
Number of subjects: 177

Group type: COMPARATOR
Intervention: Manual Vacuum Aspiration (MVA) as inpatient procedure
Number of subjects: 177
Study: 22813494

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion maintained at a target effect site concentration of 1.0 ng/ml during ventilator weaning
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group with propofol infusion stopped and remifentanil infusion also stopped during ventilator weaning
Number of subjects: 50
Study: 20571327

Group type: EXPERIMENTAL
Intervention: Multifactor approach (cognitive‐behavioral therapies, diet and physical activity counselling, 'on‐off' prescription of orlistat)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Multifactor approach
Number of subjects: 50
Study: 17270617

Group type: EXPERIMENTAL
Intervention: Standardized urodynamic testing procedures protocol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: UDS Interpretation Guidelines
Number of subjects: 20
Study: 15927733

Group type: EXPERIMENTAL
Intervention: Head rotation during whiplash-type impacts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trunk flexion during whiplash-type impacts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Head rotation or trunk flexion at the time of impact
Number of subjects: 0
Study: 12099782

Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral pizotifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous atropine or physostigmine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral L-dopa, bromocriptine or haloperidol
Number of subjects: 0
Study: 10072229

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 7586937

Group type: EXPERIMENTAL
Intervention: Moclobemide (400 mg/day for 2 months, then 200 mg/day for 1 month)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 2180817

Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low sodium diet for 3 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 18
Study: 207295

Group type: EXPERIMENTAL
Intervention: salbutamol infusion (0.15 microgram kg‐1 min‐1 for 60 min)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: practolol injection (2 mg kg‐1 for 10 min); salbutamol infusion
Number of subjects: 4

Group type: COMPARATOR
Intervention: saline injection; saline infusion
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: propranolol injection (0.3 mg kg‐1 for 10 min); salbutamol infusion
Number of subjects: 4
Study: 30239799

Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha therapy during pregnancy
Number of subjects: 72
Study: 28704419

Group type: EXPERIMENTAL
Intervention: Healthy diet rich in unsaturated fat (4-week dietary intervention)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Usual diet (control diet)
Number of subjects: 11
Study: 26112329

Group type: EXPERIMENTAL
Intervention: Dexamethasone suppression test
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Basal early morning cortisol and dehydroepiandrosterone sulfate
Number of subjects: 24
Study: 25276717

Group type: EXPERIMENTAL
Intervention: Pressure applied to the P6 acupoint using special Acubands
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group with Acubands fastened loosely on wrists
Number of subjects: 88
Study: 20500802

Group type: EXPERIMENTAL
Intervention: Cerebrolysin 10 ml
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Cerebrolysin 30 ml
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Cerebrolysin 60 ml
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 133
Study: 19427123

Group type: EXPERIMENTAL
Intervention: EMLA cream (local anaesthetic)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sorbolene treatment
Number of subjects: 39
Study: 16949521

Group type: EXPERIMENTAL
Intervention: Protease inhibitory modulating matrix (the OCR/collagen Promogran matrix, Ethicon) with dressings changed daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Good standard wound care
Number of subjects: 33
Study: 15181135

Group type: EXPERIMENTAL
Intervention: PET (Positron Emission Tomography)
Number of subjects: 32
Study: 11509468

Group type: EXPERIMENTAL
Intervention: DASH diet (n=23)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control diet (n=25)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Fruits/vegetables diet (n=24)
Number of subjects: 72
Study: 9114771

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 68

Group type: COMPARATOR
Intervention: Aspirin or Ticlopidine (Control)
Number of subjects: 68
Study: 8513847

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin pretreatment (7-day course)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study: 3552176

Group type: EXPERIMENTAL
Intervention: Cephalothin prophylaxis (25 mg/kg, four doses)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (multivitamin)
Number of subjects: 63
Study: 31696644

Group type: EXPERIMENTAL
Intervention: 600 pulses of 5-Hz rTMS
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1200 pulses of 5-Hz rTMS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 15
Study: 28832909

Group type: EXPERIMENTAL
Intervention: Single-layer unlocked sutures
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Single-layer locked sutures
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Double-layer sutures
Number of subjects: 435
Study: 25442225

Group type: EXPERIMENTAL
Intervention: Individually tailored, culturally and linguistically adapted physical activity intervention
Number of subjects: 266

Group type: COMPARATOR
Intervention: Wellness contact control
Number of subjects: 266
Study: 23269413

Group type: EXPERIMENTAL
Intervention: Abnormal MRI findings (ANE)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Normal conventional MRI findings (NNE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (term-equivalent premature neonates)
Number of subjects: 36
Study: 21992502

Group type: EXPERIMENTAL
Intervention: Exercise therapy in addition to GP care
Number of subjects: 210

Group type: COMPARATOR
Intervention: GP care alone
Number of subjects: 210
Study: 18492523

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 85

Group type: COMPARATOR
Intervention: Goal setting alone
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Metformin adherence with lifestyle change
Number of subjects: 85
Study: 16801657

Group type: EXPERIMENTAL
Intervention: Perfusion MRI
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Perfusion MRI with CBF threshold value of 1.2
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Perfusion MRI with CBF threshold value of 0.5
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Perfusion MRI with CBF threshold value of 1.4
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Perfusion MRI with CBF threshold value of 1.6
Number of subjects: 79
Study: 15539017

Group type: EXPERIMENTAL
Intervention: Shengxueling Granule (SXLG)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Prednisone (control)
Number of subjects: 86
Study: 11063063

Group type: EXPERIMENTAL
Intervention: HIV-positive speakers in a multicomponent intervention
Number of subjects: 1491

Group type: EXPERIMENTAL
Intervention: Combination of intervention and speakers
Number of subjects: 1491

Group type: COMPARATOR
Intervention: Knowledge-based curriculum (comparison condition)
Number of subjects: 1491
Study: 9408812

Group type: EXPERIMENTAL
Intervention: Methylphenidate (5 mg plus 20 mg sustained release)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8111512

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Amoxicillin (500 mg three times daily)
Number of subjects: 142
Study: 2874782

Group type: EXPERIMENTAL
Intervention: Intracapsular extraction plus contact lens (Group A)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Intracapsular extraction plus Federov implant (Group B)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Extracapsular extraction plus iridocapsular implant (Group C)
Number of subjects: 333
Study: 29633166

Group type: EXPERIMENTAL
Intervention: Vilazodone 15 mg/day
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Vilazodone 30 mg/day
Number of subjects: 529

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study: 27449253

Group type: EXPERIMENTAL
Intervention: Trauma-focused treatment (TF treatment) including Prolonged Exposure and Eye Movement Desensitization and Reprocessing therapy, 8 sessions
Number of subjects: 108
Study: 24275780

Group type: EXPERIMENTAL
Intervention: Septoplasty
Number of subjects: 72
Study: 22188037

Group type: EXPERIMENTAL
Intervention: Venowave device
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (standard care with graduated compression stockings and physiotherapy)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 20537515

Group type: EXPERIMENTAL
Intervention: Crocetin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 18543502

Group type: EXPERIMENTAL
Intervention: Lecture on air embolism
Number of subjects: 52

Group type: COMPARATOR
Intervention: Problem-based learning class
Number of subjects: 52
Study: 15954970

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) infusion, 5 mg kg(‐1).h(‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 30
Study: 12070950

Group type: EXPERIMENTAL
Intervention: Intravenous fluid at 100% of normal maintenance volumes (half‐normal saline and 5% dextrose)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Oral fluid restriction at 60% of normal maintenance volumes (breast milk by nasogastric tube)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Intravenous fluid at 100% of normal maintenance volumes
Number of subjects: 346

Group type: COMPARATOR
Intervention: Oral fluid restriction at 60% of normal maintenance volumes
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 346
Study: 11408131

Group type: EXPERIMENTAL
Intervention: Heparin-surface-modified poly(methyl methacrylate) (PMMA) IOL
Number of subjects: 31

Group type: COMPARATOR
Intervention: Soft hydrophobic acrylic IOL
Number of subjects: 31
Study: 9230719

Group type: EXPERIMENTAL
Intervention: SR27417A
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8130497

Group type: EXPERIMENTAL
Intervention: Computerized, telephone-based stress management program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 3671255

Group type: EXPERIMENTAL
Intervention: Xylose tolerance test at 3100 m and 4846 m
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oxalate loading test
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Direct fat absorption test with 100 g fat
Number of subjects: 11
Study: 29059289

Group type: EXPERIMENTAL
Intervention: Bonded retainers (BRs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vacuum‐formed retainers (VFRs)
Number of subjects: 60
Study: 27898154

Group type: EXPERIMENTAL
Intervention: Internet-based intervention for families of Veterans with PTSD
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 103
Study: 25091871

Group type: EXPERIMENTAL
Intervention: Comprehensive PPD screening and management program
Number of subjects: 2343

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2343